The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Clinical remission as defined by Crohn's disease activity index less than 150 [ Time Frame: 8 weeks ]
Clinical remission in Ulcerative colitis: Total MAYO score </= 2 [ Time Frame: 8 weeks ]
Total Mayo score of </=2, with all mayo sub-scores being 1 or less
Clinical remission in Microscopic colitis [ Time Frame: 8 weeks ]
Mean of <3 stools/day, including a mean of <1 watery stool/day over 1 week and if steroid dependent, the ability to cease steroids without increasing symptoms over baseline disease activity assessment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with active inflammatory bowel disease or microscopic collitis
Patients with inflammatory bowel disease (Crohn's disease or Ulcerative colitis) or Microscopic Colitis proven on the basis of radiology, endoscopy or histology.
Patients with clinically and endoscopically active, Crohn's Disease, Ulcerative Colitis or Microscopic Colitis
Patient must have attempted reasonable medical therapies to control their disease without sufficient response.
All patients have to be capable of attending appointments, as well completing surveys and diagnostic tests for the duration of study follow up
The patient must be able to identify a likely stool donor
Patients with an enteropathy or colitis which cannot definitively be diagnosed as Ulcerative Colitis, Crohn's disease or Microscopic colitis
Patients with concurrent Clostridium difficile infection
Women who are pregnant or intending to become pregnant in the near future (less than 6 months).
Neutrophils less than 1.0 x 109/L
Albumin less than 20g/L
Active gastrointestinal infection as identified by testing
A patient on steroids (prednisolone, budesonide) at a dose that cannot be safely tapered to zero within 6 weeks of initial FMT, due to the risk of adrenal insufficiency
Short gut syndrome and/or small intestine less than 1.5m in length as measured intra-operatively
Perforation or active internal fistulising disease or enterocutaneous fistulae.
Any patient that the clinicians feel is incapable of participating in the safe use of FMT.